M&A picked up in the third quarter but overall 2021 has been quiet on the takeover front.
Full data from the trial position the Pharmamar/Jazz small-cell lung cancer drug to remain safely on the US market.
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
The group’s determination to conquer another rare epilepsy, tuberous sclerosis complex, looks questionable.
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
The first quarter of 2021 saw fewer deals than any in recent memory.